Replies to post #158930 on Biotech Values

[jq1234]

FDA denied TEVA's CP regarding new MS drug approval without input from adcom:

http://www.regulations.gov/contentStreamer?objectId=0900006481248bf6&disposition=attachment&contentType=pdf

[jbog]

Biogen advances after upbeat comments on MS drug data
Biogen's (BIIB) shares are rising over 4% after an analyst wrote that the company's multiple sclerosis drug, Tecfidera, appears to be "crushing" its competitors.

Specifically, in just one week on the market, Tecfidera reached prescription levels that a competing drug, Novartis' (NVS) Gilenya, achieved after about three months on the market, according to ISI Group analyst Dr. Mark Schoenebaum. Moreover, Tecfidera only needs to approximately match Gilenya's performance to beat Street expectations, added the analyst, who maintained a Buy rating on Biogen. He did, however, caution that it's too early to reach definitive conclusions about Tecfidera. In late morning trading, Biogen rose $8.80, or 4.30%, to $212.